Emotional Brain's FSIAD Products Lybrido and Lybridos show High Efficacy and Safety in Phase 2B Trials

Tuesday, January 9, 2018 Clinical Trials News
Email Print This Page Comment bookmark
Font : A-A+

ALMERE, the Netherlands, January 9, 2018 /PRNewswire/ --

Emotional Brain is pleased to announce the publication of

positive phase 2B results in the authoritative Journal of Sexual Medicine. Lybrido and Lybridos were successfully tested in 497 women with Female Sexual Interest and Arousal Disorder (FSIAD) in a multicenter US-based
phase 2b trial.

The on-demand oral treatment showed significant efficacy in sexual satisfaction improvement in FSIAD women. A personalized medicine approach was used, based on individual differences in causal mechanisms involved in low sexual interest and arousal.

An effective treatment for women suffering from FSIAD is a current unmet medical need. Emotional Brain developed the on-demand solutions Lybrido and Lybridos for two specific FSIAD subtypes. Lybrido is designed for women with FSIAD as a result of a relative insensitive brain system for sexual stimuli. Lybridos is specifically designed for women with FSIAD as a result of an overactive sexual inhibition system in the brain. The results show significant increases in the primary endpoint for Lybrido, i.e. the change in satisfactory sexual events (SSE) from baseline, as compared to placebo and monotherapy. Lybridos also significantly outperformed placebo and monotherapy on the primary endpoint.

The results show that Lybrido and Lybridos are currently the most effective pharmacological treatments for FSIAD. Besides, a beneficial safety profile was observed, with very few side effects, including no interaction with alcohol intake. The Lybrido and Lybridos tablets are not only proven to be effective and safe, but the on-demand oral administration method is preferred by women, as compared to required chronic administration or alternative injectable options, as was clearly shown in a recent market research study.

Information For more information, please visit: http://www.emotionalbrain.nl

Adriaan Tuiten, PhD (CEO) Kim van Rooij, MD, PhD (CSO)

SOURCE Emotional Brain

Advertisement


Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store